lecture 4 purity test: definition of transparency, color and reaction medium solutions of drugs....
TRANSCRIPT
Lecture 4
Purity test definition of transparency color and reaction medium solutions of drugs
Purity test impurities their types and methods of determination Reference
solutions Test limit the amount of inorganic impurities in medicines
PhD Logoyda Liliya
Preformulationbull Preformulation is branch of Pharmaceutical science that
utilizes biopharmaceutical principles in the determination of physicochemical properties of the drug substance
bull Prior to the development of any dosage form new drug it is essential that certain fundamental physical amp chemical properties of drug powder are determined
bull This information may dictate many of subsequent event amp approaches in formulation development
bull This first learning phase is called as preformulation
2
INTRODUCTION
DEFINITION-Investigation of physico-chemical properties of the new drug compound that could affect drug performance and development of an efficacious dosage formrdquo
Preformulation commences when a newly synthesized drug shows a sufficient pharmacologic promise in animal model to warrant evaluation in man
3
e) Potential hazards
f) Initial bulk lots
- Lot number
- Crystallization solvent(s)
- Particle size range
- Melting point
- volatiles
g) Analytical methods
- HPLC assay
- TLC assay
- UV Visible spectroscopyContdhellip
4
Preliminary Evaluation
ORGANOLEPTIC PROPERTIES
COLOR ODOUR TASTE
OFF-WHITE PUNGENT ACIDIC
CREAM-YELLOW SULFUROUS BITTER
SHINY FRUITY SWEET
AROMATIC TASTELESS
ODOURLESS TASTELESS
5
bull The substance may exhibit an inherent odor characteristic of major functional groups present
bull Odor greatly affects the flavor of a preparation or food stuff
Taste-bull If taste is considered as unpalatable consideration is
to be given to the use of a less soluble chemical form of the drug
bull The odour and taste may be suppressed by using appropriate flavors and excipients or by coating the final product
6
Odour
PURITY
bull Designed to estimate the levels of all known amp significant impurities amp contaminates in the drug substance under evaluation
bull Study performed in an analytical research amp development group
bull It is another parameter which allows for comparison with subsequent batches
bull Occasionally an impurity can affect stabilityeg - Metal contamination
- Appearance
7
bull The techniques used for characterizing the purity of a drug are the same as those used for other purpose in a preformulation study
bull Thin layer chromatography is a wide ranging applicability amp is an excellent tool for characterizing the purity
bull HPLC paper chromatography amp gas chromatography are also useful
bull More quantitative information can be obtained by using quantitative differential scanning colorimetry
8
PURITY
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Preformulationbull Preformulation is branch of Pharmaceutical science that
utilizes biopharmaceutical principles in the determination of physicochemical properties of the drug substance
bull Prior to the development of any dosage form new drug it is essential that certain fundamental physical amp chemical properties of drug powder are determined
bull This information may dictate many of subsequent event amp approaches in formulation development
bull This first learning phase is called as preformulation
2
INTRODUCTION
DEFINITION-Investigation of physico-chemical properties of the new drug compound that could affect drug performance and development of an efficacious dosage formrdquo
Preformulation commences when a newly synthesized drug shows a sufficient pharmacologic promise in animal model to warrant evaluation in man
3
e) Potential hazards
f) Initial bulk lots
- Lot number
- Crystallization solvent(s)
- Particle size range
- Melting point
- volatiles
g) Analytical methods
- HPLC assay
- TLC assay
- UV Visible spectroscopyContdhellip
4
Preliminary Evaluation
ORGANOLEPTIC PROPERTIES
COLOR ODOUR TASTE
OFF-WHITE PUNGENT ACIDIC
CREAM-YELLOW SULFUROUS BITTER
SHINY FRUITY SWEET
AROMATIC TASTELESS
ODOURLESS TASTELESS
5
bull The substance may exhibit an inherent odor characteristic of major functional groups present
bull Odor greatly affects the flavor of a preparation or food stuff
Taste-bull If taste is considered as unpalatable consideration is
to be given to the use of a less soluble chemical form of the drug
bull The odour and taste may be suppressed by using appropriate flavors and excipients or by coating the final product
6
Odour
PURITY
bull Designed to estimate the levels of all known amp significant impurities amp contaminates in the drug substance under evaluation
bull Study performed in an analytical research amp development group
bull It is another parameter which allows for comparison with subsequent batches
bull Occasionally an impurity can affect stabilityeg - Metal contamination
- Appearance
7
bull The techniques used for characterizing the purity of a drug are the same as those used for other purpose in a preformulation study
bull Thin layer chromatography is a wide ranging applicability amp is an excellent tool for characterizing the purity
bull HPLC paper chromatography amp gas chromatography are also useful
bull More quantitative information can be obtained by using quantitative differential scanning colorimetry
8
PURITY
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
INTRODUCTION
DEFINITION-Investigation of physico-chemical properties of the new drug compound that could affect drug performance and development of an efficacious dosage formrdquo
Preformulation commences when a newly synthesized drug shows a sufficient pharmacologic promise in animal model to warrant evaluation in man
3
e) Potential hazards
f) Initial bulk lots
- Lot number
- Crystallization solvent(s)
- Particle size range
- Melting point
- volatiles
g) Analytical methods
- HPLC assay
- TLC assay
- UV Visible spectroscopyContdhellip
4
Preliminary Evaluation
ORGANOLEPTIC PROPERTIES
COLOR ODOUR TASTE
OFF-WHITE PUNGENT ACIDIC
CREAM-YELLOW SULFUROUS BITTER
SHINY FRUITY SWEET
AROMATIC TASTELESS
ODOURLESS TASTELESS
5
bull The substance may exhibit an inherent odor characteristic of major functional groups present
bull Odor greatly affects the flavor of a preparation or food stuff
Taste-bull If taste is considered as unpalatable consideration is
to be given to the use of a less soluble chemical form of the drug
bull The odour and taste may be suppressed by using appropriate flavors and excipients or by coating the final product
6
Odour
PURITY
bull Designed to estimate the levels of all known amp significant impurities amp contaminates in the drug substance under evaluation
bull Study performed in an analytical research amp development group
bull It is another parameter which allows for comparison with subsequent batches
bull Occasionally an impurity can affect stabilityeg - Metal contamination
- Appearance
7
bull The techniques used for characterizing the purity of a drug are the same as those used for other purpose in a preformulation study
bull Thin layer chromatography is a wide ranging applicability amp is an excellent tool for characterizing the purity
bull HPLC paper chromatography amp gas chromatography are also useful
bull More quantitative information can be obtained by using quantitative differential scanning colorimetry
8
PURITY
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
e) Potential hazards
f) Initial bulk lots
- Lot number
- Crystallization solvent(s)
- Particle size range
- Melting point
- volatiles
g) Analytical methods
- HPLC assay
- TLC assay
- UV Visible spectroscopyContdhellip
4
Preliminary Evaluation
ORGANOLEPTIC PROPERTIES
COLOR ODOUR TASTE
OFF-WHITE PUNGENT ACIDIC
CREAM-YELLOW SULFUROUS BITTER
SHINY FRUITY SWEET
AROMATIC TASTELESS
ODOURLESS TASTELESS
5
bull The substance may exhibit an inherent odor characteristic of major functional groups present
bull Odor greatly affects the flavor of a preparation or food stuff
Taste-bull If taste is considered as unpalatable consideration is
to be given to the use of a less soluble chemical form of the drug
bull The odour and taste may be suppressed by using appropriate flavors and excipients or by coating the final product
6
Odour
PURITY
bull Designed to estimate the levels of all known amp significant impurities amp contaminates in the drug substance under evaluation
bull Study performed in an analytical research amp development group
bull It is another parameter which allows for comparison with subsequent batches
bull Occasionally an impurity can affect stabilityeg - Metal contamination
- Appearance
7
bull The techniques used for characterizing the purity of a drug are the same as those used for other purpose in a preformulation study
bull Thin layer chromatography is a wide ranging applicability amp is an excellent tool for characterizing the purity
bull HPLC paper chromatography amp gas chromatography are also useful
bull More quantitative information can be obtained by using quantitative differential scanning colorimetry
8
PURITY
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
ORGANOLEPTIC PROPERTIES
COLOR ODOUR TASTE
OFF-WHITE PUNGENT ACIDIC
CREAM-YELLOW SULFUROUS BITTER
SHINY FRUITY SWEET
AROMATIC TASTELESS
ODOURLESS TASTELESS
5
bull The substance may exhibit an inherent odor characteristic of major functional groups present
bull Odor greatly affects the flavor of a preparation or food stuff
Taste-bull If taste is considered as unpalatable consideration is
to be given to the use of a less soluble chemical form of the drug
bull The odour and taste may be suppressed by using appropriate flavors and excipients or by coating the final product
6
Odour
PURITY
bull Designed to estimate the levels of all known amp significant impurities amp contaminates in the drug substance under evaluation
bull Study performed in an analytical research amp development group
bull It is another parameter which allows for comparison with subsequent batches
bull Occasionally an impurity can affect stabilityeg - Metal contamination
- Appearance
7
bull The techniques used for characterizing the purity of a drug are the same as those used for other purpose in a preformulation study
bull Thin layer chromatography is a wide ranging applicability amp is an excellent tool for characterizing the purity
bull HPLC paper chromatography amp gas chromatography are also useful
bull More quantitative information can be obtained by using quantitative differential scanning colorimetry
8
PURITY
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull The substance may exhibit an inherent odor characteristic of major functional groups present
bull Odor greatly affects the flavor of a preparation or food stuff
Taste-bull If taste is considered as unpalatable consideration is
to be given to the use of a less soluble chemical form of the drug
bull The odour and taste may be suppressed by using appropriate flavors and excipients or by coating the final product
6
Odour
PURITY
bull Designed to estimate the levels of all known amp significant impurities amp contaminates in the drug substance under evaluation
bull Study performed in an analytical research amp development group
bull It is another parameter which allows for comparison with subsequent batches
bull Occasionally an impurity can affect stabilityeg - Metal contamination
- Appearance
7
bull The techniques used for characterizing the purity of a drug are the same as those used for other purpose in a preformulation study
bull Thin layer chromatography is a wide ranging applicability amp is an excellent tool for characterizing the purity
bull HPLC paper chromatography amp gas chromatography are also useful
bull More quantitative information can be obtained by using quantitative differential scanning colorimetry
8
PURITY
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
PURITY
bull Designed to estimate the levels of all known amp significant impurities amp contaminates in the drug substance under evaluation
bull Study performed in an analytical research amp development group
bull It is another parameter which allows for comparison with subsequent batches
bull Occasionally an impurity can affect stabilityeg - Metal contamination
- Appearance
7
bull The techniques used for characterizing the purity of a drug are the same as those used for other purpose in a preformulation study
bull Thin layer chromatography is a wide ranging applicability amp is an excellent tool for characterizing the purity
bull HPLC paper chromatography amp gas chromatography are also useful
bull More quantitative information can be obtained by using quantitative differential scanning colorimetry
8
PURITY
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull The techniques used for characterizing the purity of a drug are the same as those used for other purpose in a preformulation study
bull Thin layer chromatography is a wide ranging applicability amp is an excellent tool for characterizing the purity
bull HPLC paper chromatography amp gas chromatography are also useful
bull More quantitative information can be obtained by using quantitative differential scanning colorimetry
8
PURITY
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Solubilization is thought to occur by virtue of the solute dissolving in or being adsorbed onto the micelle
Thus the ability of surfactant solution to dissolved or solubilize water insoluble materials starts at the CMC and increase with increase in the concentration of micelles
Solubilization of any material in any solvent depends on proper selection of solubilising agents
9
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
The amount of substance that passes into solution in order to establish equilibrium at constant temperature and pressure to produce a saturated solution
10
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
If solubility is lt1mgml indicates need for salt formation to improve solubility
If solubility is lt1mgml in pH= 1 to 7 preformulation study should be initiated
Solubility should ideally be measured at two temperatures 4degC and 37degC
4degC to ensure Physical stability
37degC to support Biopharmaceutical evaluation11
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Description Parts of solvent required for one part of solute
Very soluble lt 1 Freely soluble 1 - 10
Soluble 10 - 30 Sparingly soluble 30 - 100 Slightly soluble 100 - 1000
Very slightly soluble
1000 - 10000
Insoluble gt 10000 12
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Preformulation solubility studies focus on drug solvent system that could occur during the delivery of drug candidate
For eg A drug for oral administration should be examined for solubility in media having isotonic chloride ion concentration and acidic pH
13
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Analytic method that are particularly useful for solubility measurement include HPLC UV spectroscopy Fluorescence spectroscopy and Gas chromatography
Reverse phase HPLC offer accurate and efficient mean of collecting solubility data of drug
14
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Methods of Preparations
bull Melting Method
bull Solvent Method
bull Melting - Solvent Method
bull Hot Melt Extrusion Technique
15
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
1 Melting Method or Fusion Method
bull The physical mixture of a drug and water soluble carrier is heated until it melts
bull The melt is then cooled and solidified rapidly in an ice bath with vigorous stirring
bull The final solid mass is crushed pulverized and sieved
bull To facilitate faster solidification the homogenous melt is poured in the form of a thin layer onto stainless steel plate and cooled by flowing air or water on the opposite side of the plate
16
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull Advantages bull Simplicity of methodbull Supersaturation of a solute or a drug in a system can
often be obtained by quenching the melt rapidly from high temperature
bull Disadvantage bull Some drugs or carriers may decompose or evaporate
during fusion process at high temperatures
eg succinic acid used as a carrier for griseofulvin is quite volatile and may also partially decompose by dehydration near its melting point
17
1 Melting Method or Fusion Method
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
2 Solvent Method
bull They are prepared by dissolving a physical mixture of two solid components in a common solvent followed by evaporation of the solvent
bull The method is used to prepare solid dispersions of griseofulvin-polyvinylpyrrolidone sulphathiazole - pvp
18
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull Advantage - Thermal decomposition of drugs or carriers can be
prevented because of low temperature required for the evaporation of organic solvents
bull Disadvantages
- High cost of preparation
- Difficulty in completely removing the solvent
- Difficulty in producing crystal forms
19
2 Solvent Method
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
3 Melting Solvent Method bull It is prepared by first dissolving the drug in a
suitable solvent and then incorporating this solution in a melt of PEG without removing the solvent
bull Advantages
Same as above two methods
bull Disadvantage
From practical stand point it is only limited to drugs with a low therapeutic dose eg below 50mg
20
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull Advantages - There are no concerns with solvent handling or
recovery after processing- It is simple and continuous process for preparation of tablets and granulations- The process is faster and there were fewer steps
than the wet granulation method - Can be used for formulating sustained release granules
eg Diltiazem granules21
4 Hot Melt Extrusion Method
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Methods of Determination of Solid Dispersion Systems
bull Thermal analysis
a) Cooling curve method
b) Thaw-melt method
c) Thermoscopic method
d) Differential thermal analysis (DTA)
e) Zone Melting Method
22
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull X-Ray diffraction Method
bull Microscopic method
bull Spectroscopic method
bull Thin layer chromatography
bull Solubility determinations
23
Methods of Determination of Solid Dispersion Systems
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
e) Zone Melting Method
- It is primarily used for ultra purification of metal and inorganic and
organic metal
24
A Thermal Analysis
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
B X-Ray Diffraction Method
bull In this method the intensity of x-ray diffraction or reflection from a sample is measured as a function of diffraction angles
bull Counter and film methods detect diffraction intensity bull Counter method provides better resolution of
diffraction and relative intensity which can be easily compared
bull This method is used to characterize physico-chemical properties of Griseofulvin dispersed in PEG 4000 and 6000
25
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
C Microscopic Method
bull It has been used to study polymorphism and morphology of solid dispersion
bull The fine particles of crystallization in glass PVP can be easily detected by polarizing microscope
bull The resolution of electron microscope was used to study dispersed particle size of iopanic acid in PVP
26
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
D Spectroscopic Method bull In the UV study the spectra of pure drug and
the dispersed drug are scanned
bull eg The spectrum of the dispersed beta ndashcarotene resembles that betandashcarotene is dissolved in organic solvents but do not indicate the molecular dispersion of drug in polymer
27
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
E Thin Layer Chromatography
bull TLC characteristics of pure and dispersed drugs are studied to test whether the drugs are decomposed by process
bull A single spot with same lsquoRf rsquovalue is expected for both the pure and processed samples in thin layer plate
28
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
F Solubility determinations bull Results from aqueous solubility studies of drug
in various concentrations of carrier would indicate interactions between drug and carrier
bull Such studies indicated weak or insignificant interactions between griseofulvin and PEG 6000
bull Increased rate of dissolution due to solubility of the drug by carrier can be predicted by this method
29
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Pharmaceutical Applications
bull To obtain a homogenous distribution of small amount of drugs at solid state
bull To stabilize unstable drugsbull To dispense liquid or gaseous compoundsbull To formulate a faster release priming dose in a
sustained release dosage formbull To formulate sustained release dosage or
prolonged release regimens of soluble drugs by using poorly soluble or insoluble carriers
30
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Chemistry of b-cyclodextrin
bull Cyclodextrine molecule have cylindrical shape with central axial cavity and resembles with shape of truncated cone
bull The interior cavity is hydrophobic and the outside of the molecule is hydrophilic
31
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Characteristics of β-cyclodextrin
bull Glucose unit ndash 07bull Molecular wt ndash 1135bull Solubility ndash 185g100ml
bull Cavity diameter ndash 64 Ao
bull Diameter of outer periphery ndash 154 Ao
bull Approx vol of cavity ndash 262 (Ao)3
32
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Method of preparation of -cyclodextrin complex
bull Physical mixture method
bull Kneading method
bull Co-evaporation method
bull Solid dispersion method
bull Spray drying method
bull Neutralization method
33
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Physical mixture method
bull Here the drug and b-cyclodextrin (12) are mixed physically with spatula amp then the pulverized powder is passed through 100
bull Eg Diclofinac sodium
34
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Kneading method
bull Here the b-cyclodextrin is dissolved in small vol of water-methanol solution(64)
bull To the above solution required drug is added in small amount
bull The slurry is then kneaded for 45 min amp dried at 45oc
bull The dried mass is pulverized and sieved through 100
bull Eg Nimesulide Omeprazole
35
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Co-evaporation method
bull In this method aq solution of b-cyclodextrin is added to an alcoholic solution of drug
bull The resulting mix is stirred for 1 hr amp evaporated at 45oc until it is dried
bull The dried mass is pulverized and sieved through 100
bull Eg Steroids amp Diclofenac sodium
36
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Solid dispersion method
bull Here the drug amp molar qty of b-cyclodextrin is dissolved in methanol
bull The solution is then evaporated in vacuum at 40oc with rotatory evaporator
bull The powder is stored under vacuum in dessicator for 3 days amp analysed
bull Eg Rifampicin
37
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Spray drying methodbull In this the drug amp double molar of β-cyclodextrin are
dissolved in methanol
bull The solution was then spray dried under foll conditions ndash
Feed rate ndash 10 mlmin Inlet temp - 95oc Outlet temp - 65oc Press ndash 5 bar Drying air ndash 35 m3
38
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull The powder is then collected amp stored under vacuum in dessicator for 3 days amp analysed
bull Eg Naproxene
39
Spray drying method
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Neutralization method
bull Here the drug amp b-cyclodextrin are dissolved in 01N HCl amp then 01N NaOH is added to precipitate the complex at pH-75
bull The ppt is washed with distilled water
bull Then it is pulverized amp sieved through 90 and stored in dessicator over fused CaCl2
bull Eg Ketoconazole
40
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Applications
bull To increase aq solubilitybull To increase dissolution rate of drugbull To improve bioavailability of drugbull To increase chemicalphysical stability bull To decrease drug irritation
41
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Crystallinity
bull Crystal habit amp internal structure of drug can affect bulk amp physicochemical property of molecule
bull Crystal habit is description of outer appearance of crystal
bull Internal structure is molecular arrangement within the solid
42
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull Change with internal structure usually alters crystal habit
Eg Conversion of sodium salt to its free acid form produce both change in internal structure amp crystal habit
43
Crystallinity
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Different shapes of crystalsbull Cubic or isometric - not
always cube shaped Also find as octahedrons (eight faces) and dodecahedrons (10 faces)
bull Tetragonal- similar to cubic crystals but longer along one axis than the other forming double pyramids and prisms
bull Orthorhombic - like tetragonal crystals except not square in cross section (when viewing the crystal on end) forming rhombic prisms or dipyramids (two pyramids stuck together)
bull Hexagonal - six-sided prisms When you look at the crystal on-end the cross section is a hexagon
bull Trigonal - possess a single 3-fold axis of rotation instead of the 6-fold axis of the hexagonal division
bull Triclinic - usually not symmetrical from one side to the other which can lead to some fairly strange shapes
bull Monoclinic - like skewed tetragonal crystals often forming prisms and double pyramids
44
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
45
Different shapes of crystals
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull Depending on internal structure compounds is classified as
1 Crystalline 2 Amorphous bull Crystalline compounds are characterized by
repetitious spacing of constituent atom or molecule in three dimensional array
bull In amorphous form atom or molecule are randomly placed
46
Different shapes of crystals
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull Solubility amp dissolution rate are greater for amorphous form then crystalline as amorphous form has higher thermodynamic energy
Eg Amorphous form of Novobiocin is well absorbed whereas crystalline form results in poor absorption
47
Different shapes of crystals
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Polymorphism
bull It is the ability of the compound to crystallize as more than one distinct crystalline species with different internal lattice
bull Different crystalline forms are called polymorphs
bull Polymorphs are of 2 types 1 Enatiotropic 2 Monotropic
48
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull The polymorph which can be changed from one form into another by varying temp or pressure is called as Enantiotropic polymorph
Eg Sulfur
bull One polymorph which is unstable at all temp amp pressure is called as Monotropic polymorph
Eg Glyceryl stearate
49
Polymorphism
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull Polymorph differ from each other with respect to their physical property such as
Solubility
Melting point
Density
Hardness
Compression characteristic
50
Polymorphism
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
bull During preformulation it is important to identify the polymorph that is stable at room temp
Eg 1)Chloromphenicol exist in AB amp C forms of these B form is more stable amp most preferable 2)Riboflavin has III amp III forms the III form shows 20 times more water solubility than form I
51
Polymorphism
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Stability testinghellip
52
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Why Stabilitybull Provide a evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental factors such ashellip temperature Humidity and light
bull Establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions
bull Because physical chemical or microbiological changes might impact the efficiency and security of the final product
53
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Where and WhyStability Studies are preformed on bull Drug Substances (DS) The unformulated drug
substance that may subsequently be formulated with excipients to produce the dosage form
bull Drug Products (DP) The dosage form in the final immediate packaging intended for marketinghelliphellip
bull controlled and documented determination of acceptable changes of the drug substance or drug product
54
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
What are changes
bull Physical changes bull Appearance bull Melting point bull Clarity and color of solution bull moisture bull Crystal modification (Polymorphism) bull Particle sizebull Chemical changes bull Increase in Degradation bull Decrease of Assaybull Microbial changes 55
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Chemical degradation studiesbull Hydrolysis
bull Oxidation
bull Reduction
bull Decarboxylation
bull Photolysis56
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Stability studies at different stages
bull Stress- and accelerated Testing with drug substances
bull Stability on pre-formulation batches
bull Stress testing on scale-up Batches
bull Accelerated and long term testing for registration
bull On-going Stability testing
bull Follow-up Stabilities57
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Scope bull Solubility Profile bull Hygroscopicity bull Thermal stability (Melting point Polymorphism) bull Chemical stability1048708 1 Batch1048708 Up to 3 month
Scope bull Determination of expire date bull Determination of preliminary specifications bull Release of clinical batches bull Monitoring of samples during the clinical phases bull Definition of storage conditions bull Definition of Tests for registration stability 1048708 Up to 36 month
1048708 Selection of samples bull API excipient batches1048708 Scope bull Appearance bull Appropriate physical-chemical parameter bull Assay Degradation products1048708 Up to 3 month
58
Stability studies at different stages
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Testing scope for Solid dosage
bull Physical-chemical properties ndash Appearance ndash Elasticity ndash Mean mass ndash Moisture ndash Hardness ndash Disintegration ndash Dissolutionbull Chemical properties ndash Assay ndash Degradation bull Microbial properties bull Container closure system properties ndash Functionality tests (eg extraction from blister)
Tablet amp Capsule
59
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Testing scope for Oral liquid
formbull Physical-chemical properties ndash pH ndash Color amp clarity of solution ndash Viscosity ndash Particle size distribution (for oral suspensions only)bull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
60
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Testing scope for LIQUID FORMS for inj and
PARENTRALbull Physical-chemical properties ndash pH ndash Loss on weight ndash Color amp clarity of solutionbull Chemical properties ndash Assay ndash Degradation products ndash Degradation preservatives ndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
61
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Testing scope for SEMI LIQUID FORMS
bull Physical-chemical properties ndash Appearance odor homogenesity consistency ndash Loss on weight Viscosity ndash Content uniformity (within the container)bull Chemical properties ndash Assay ndash Degradation products amp preservatives ndash Content preservatives ndash Degradationndash Content antioxidantsbull Microbial properties bull Container closure system properties ndash Functionality tests
62
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Climatic Zones Storage conditions
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone I
Temperate
Japan United Kingdom Northern Europe
Canada Russia United States
20 20 42 21 45
Climatic Zone II
Mediterranean Subtropical
Japan United States Southern Europe
264 22 52 25 60
63
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Climatic Zone
Countries
Calculated data
Temp MKT humidity degC degC rh
Derived data
Temp humidity degC rh
Climatic Zone III
Hot dry
Iran Iraq Sudan
264 279 35 30 35
Climatic Zone IV
Hot humid
Brazil Ghana Indonesia Nicaragua
Philippines
267 274 76 30 70
64
Climatic Zones Storage conditions
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
ICH Guidelines
bull Quality Guidelines ldquoQrdquo (chemical and pharmaceutical QA) ndash details see next slidebull Safety Guidelines ldquoSrdquo (in vitro and in vivo pre-clinical studies) ndash covering Carcinogenicity Testing Genotoxicity Testing Toxicokinetics and Pharmacokinetics hellip etcbull Efficacy Guidelines ldquoErdquo (clinical studies in human subject) ndash Covering clinical safety Dose Response Studies Good Clinical Practices Clinical evaluation hellip etcbull Multidisciplinary Guidelines ldquoMrdquo ndash Covering Medical Terminology Electronic Standards for Transmission of Regulatory Information helliphellip etc ndash Important for Stability raquo Guideline M4 The Common Technical Document (CTD)
65
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
ICH Q-Guidelines (Quality)bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV (Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
66
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Q1A(R2) Stability testing of New Drug Substances amp Products
bull Stability Testing in Climatic Zone I and II (Q1A)bull Photostability Testing (Q1B)bull Stability Testing for New Dosage Forms (Q1C)bull Bracketing and Matrixing Designs (Q1D)bull Evaluation of Stability Data (Q1E)bull Stability Testing in Climatic Zones III and IV
(Q1F)bull Validation of Analytical Procedures (Q2)bull Impurities (Q3)bull Biotechnological Products (Q5)bull Specifications (Q6)
67
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Study
Storage condition
Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
Drug substances - General case
Drug substances - intended for storage in a RefrigeratorStudy Storage condition Minimum time period
covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
68
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Drug substancesProduct- intended for storage in Freezer
Study Storage condition Minimum time period covered by data at submission
Long term -20degC plusmn 5degC 12 months
Drug products - General caseStudy Storage condition Minimum time period
covered by data at submission
Long term 25degC plusmn 2degC 60 plusmn 5 rh or
30degC plusmn 2degC 65 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 40degC plusmn 2degC 75 plusmn 5 rh 6 months
69
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Drug products - packaged in Semi-permeable containers
Study Storage condition Minimum time period covered by data at submission
Long term 25degC plusmn 2degC 40 plusmn 5 rh or
30degC plusmn 2degC 35 plusmn 5 rh
12 months
Intermediate 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Accelerated 30degC plusmn 2degC 65 plusmn 5 rh 6 months
Drug products - intended for storage in a Refrigerator
Study Storage condition Minimum time period covered by data at submission
Long term 5degC plusmn 3degC 12 months
Accelerated 25degC plusmn 2degC 60 plusmn 5 rh 6 months
70
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-
Thank You
71
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Slide 32
- Slide 33
- Slide 34
- Slide 35
- Slide 36
- Slide 37
- Slide 38
- Slide 39
- Slide 40
- Slide 41
- Slide 42
- Slide 43
- Slide 44
- Slide 45
- Slide 46
- Slide 47
- Slide 48
- Slide 49
- Slide 50
- Slide 51
- Slide 52
- Slide 53
- Slide 54
- Slide 55
- Slide 56
- Slide 57
- Slide 58
- Slide 59
- Slide 60
- Slide 61
- Slide 62
- Slide 63
- Slide 64
- Slide 65
- Slide 66
- Slide 67
- Slide 68
- Slide 69
- Slide 70
- Slide 71
-